News

Chiltern closes its Theorem buy, doubling its workforce

U.K. CRO Chiltern has wrapped up its acquisition of former U.S. competitor Theorem Clinical Research, expanding its payroll and global reach in the process.

PRA adding 150 jobs amid Pennsylvania expansion push

PRA Health Sciences is building up its presence in Pennsylvania, adding 150 jobs with plans to dial up recruitment over the next two years.

Accelovance inks a nonprofit partnership for melanoma trials

CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.

AMRI turns up its revenue guidance after a $174M buyout

AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.

WuXi brings its genomic heft to Chinese patients with hospital pact

WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.

Evotec upsizes its 2015 projections after a string of partnering deals

German research outfit Evotec is dialing up its full-year revenue expectations thanks to a series of contract wins.

Aragen licenses a protein technology to speed up biologics R&D

CRO Aragen Biosciences signed a deal with Dutch service provider ProteoNic Biotechnology to get its hands on a protein-production technology it believes can improve biologics development.

Rho snags a $120M federal contract with NIH

Private CRO Rho inked its largest-ever federal contract, signing a 7-year deal with the U.S. National Institutes of Health that will pay out about $16.5 million each year.

Evotec teams up with Pfizer for fibrosis R&D

Hybrid R&D outfit Evotec signed a deal with Pfizer to collaborate on tissue fibrosis research, lending its expertise and discovery technology to the pharma giant in exchange for a cut of the benefits.

Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis

Swedish contract drugmaker Recipharm signed a deal with neighboring LobSor Pharmaceuticals to manufacture the company's new treatment for Parkinson's disease, all the while discussing a partnership with Novartis in the field of eye care.

Icon teams up with IBM to accelerate clinical trial startup

CRO giant Icon is working with IBM in hopes of making clinical trials more efficient, tapping the company's famed Watson technology with an eye on speeding up recruitment and site selection.

Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15

Catalent watched as some unfavorable currency trends sapped its fiscal year revenue growth, but the company closed out its transformational year with a major increase in profits that management said is a sign of things to come.

Britain's NHS signs off on inVentiv's consent tech

The U.K.'s National Health Service has approved the use of inVentiv Health's informed consent technology, another victory for the CRO's pioneering software.

PPD partners up to better track trial events

PPD has reached out to clinical trial software provider Cisys LifeSciences to get its hands on technology the company believes can improve the process by which investigators examine and adjudicate safety events.

WuXi looks to Japan for manufacturing growth

WuXi PharmaTech's small-molecule business won approval to produce drugs in Japan, extending the CRO's reach as it looks to beef up its manufacturing revenue.

Chinese drugmaker trades $200M for CDMO Cytovance

China's Shenzhen Hepalink Pharmaceutical signed a deal to acquire contract drugmaker Cytovance Biologics for $205.7 million in cash, buying into the U.S.'s burgeoning market for large-molecule treatments.

BioClinica opens an app umbrella to unite researchers

Clinical trial technology outfit BioClinica has created what it's calling an app exchange, looking for new software that can help physicians and drug developers through the company's cloud-based data service.

AMRI signs on to help Saneca develop opium-based drugs

Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.

INC Research builds general medicine, CNS divisions with two EVP promotions

Leading CRO INC Research is boosting its upper echelon in the areas of general medicine and central nervous system R&D, promoting two key members.

WuXi inks lab testing pact with Chinese Lee's Pharm

Chinese small-cap Lee's Pharm has signed CRO WuXi PharmaTech as its exclusive lab testing service to bolster the company's R&D program.